Study #2020-0160
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Azacitidine
Description
The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
Study phase:
Physician name:
Jonathan Gill
Department:
Pediatrics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.